首页>
外国专利>
Combination therapy for the treatment of uveal melanoma
Combination therapy for the treatment of uveal melanoma
展开▼
机译：联合疗法治疗无过马英瘤
展开▼
页面导航
摘要
著录项
相似文献
摘要
Synergistic drug combination with small molecule PAC-1 for uveal or cutaneous melanoma. There are currently no targeted drug therapies for mutations associated with uveal melanoma. Despite primary radiation or surgical treatment, up to 50% of patients eventually develop metastatic disease, and there is no standard treatment or treatment proven to improve overall survival. The drug combination with PAC 1 allows the use of lower doses of this compound that result in cancer cell death in uveal melanoma. The drug combination of PAC-1 and the kinase inhibitor entrectinib showed a synergistic effect on the uveal melanoma cell line. Specifically, PAC-1 and entrectinib are synergistic against wild-type and mutant uveal melanoma cell lines (eg, GNAQ and GNA11).
展开▼
